[go: up one dir, main page]

US2995489A - Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid - Google Patents

Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid Download PDF

Info

Publication number
US2995489A
US2995489A US671417A US67141757A US2995489A US 2995489 A US2995489 A US 2995489A US 671417 A US671417 A US 671417A US 67141757 A US67141757 A US 67141757A US 2995489 A US2995489 A US 2995489A
Authority
US
United States
Prior art keywords
diethylaminoethyl
ethyl
preanesthetic
obtaining
sedation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US671417A
Inventor
John L Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US671417A priority Critical patent/US2995489A/en
Application granted granted Critical
Publication of US2995489A publication Critical patent/US2995489A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids

Definitions

  • the invention relates to the compound, I-(Z-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid, in dosage unit form suitable for use as a preanesthetic composition.
  • the compound 1-(2-diethylaminoethyl)-5- ethyl-S-phenylbarbituric acid and hydrochloride has the following structural formula:
  • a preanesthetic medicament Among the desirable actions of a preanesthetic medicament are the counteracting of respiratory irregularities, cardiac irregularities and excessive flow of mucous and saliva. In general, such medication makes anesthesia more safe and comfortable for the patient and more etficient for the surgeon. Further usfulness resides in raising the patients threshold of reflex exitability to allow the use of inhalant anesthetics such as ethylene and nitrous oxide.
  • preanesthetic medications comprise a mixture of a narcotic such as morphine, meperidine, methadone or a barbiturate with an anti-sialogogue such as atrophine and scopolamine, that is, an agent which inhibits secretions of the respiratory tract and the salivary glands.
  • a narcotic such as morphine, meperidine, methadone or a barbiturate
  • an anti-sialogogue such as atrophine and scopolamine
  • a further object is to prepare said dosage forms in solid and liquid carriers suitable for oral, suppository and injectable administration.
  • the compound 1-(2-diethyaminoethyl)-5-ethyl-S-phenylbarbituric acid possesses properties which makes it highly desirable as a preanesthctic medicament.
  • the compound causes inhibition of respiratory tract secretions and salivary gland secretion. It exhibits a further action in counteracting cardiac arrhythmic, that is, it maintains normal cardiac rhythm. This latter condition is often disrupted in the subsequent state of general anesthesia. Furthermore, it is expected that it will reduce reflex excitability and apprehension.
  • the effective clinical dose for adults ranges from about 10 mg. per day upwardly when injected directly into the circulatory body fluids of the patient. In children, the dosage ranges are correspondingly lower according to age and weight of the child.
  • This drug may be adnun- Patented Aug. 8, 1961 istered by hypodermic syringe in the form of a sterile water solution of said compound prepared to the desired concentration.
  • the compound can be made available n said fresh solution form or in powder form present in capsules or vials and other carriers which allow easy conversion to the solution form.
  • the drug may be also administered orally in the form of tablets, capsules, powder or in a flavored, liquid form.
  • a suppository form for rectal administration can also be prepared by combining the drug with appropriate waxes.
  • a preferred form of oral administration is 10 mg. scored tablets which will provide the minimum dose for children and will provide, in multiples, amounts up to the maximum dose.
  • the minimum dose for children and will provide, in multiples, amounts up to the maximum dose.
  • l-(2-diethylaminoethyl)-5-ethyl-5-phenthe active material with or without its adjuvant materials may be placed in a soft or hard gelatin capsule and administered in capsule form.
  • a solution dose form is made.
  • the solubility of the active compound, while limited, is still sufiicient to prepare a dosage level suitable for therapeutic administration.
  • a solution dosage form can contain from about 2 ing/cc. to 5 mg./cc. of active ingredient (10 to 25/mg. per teaspoon).
  • a liquid pharmaceutical dosage form of greater concentration may also be prepared by compounding the active material with suspending agents such as acacia or carboxymethylcellulose along with the usual flavoring materials. Such a liquid preparation is particularly suitable for children and infirm persons who have difficulty swallowing a tablet or capsule.
  • Sterile, isotonic, liquid forms are prepared for injection into the body by placing the desired amount of active ingredient into sterile water, adjusting the osmotic tension to coincide with the osmotic tension of body fluids, sealing said solution in an ampoule and sterilizing said ampoule.
  • the ampoules are sterilized in an autoclave at 121 C. at 10 lbs. pressure for 20 minutes. Immediately thereafter the ampoules are removed and cooled in running water.
  • the prepared ampoulcs contain a 2% solution of l-(2-diethyluminoethyl)-5-ethyl-5- phenylbarbituric acid which is suitable for introduction into the body by injection.
  • EXAMPLE II The compound, 1 (Z-diethylaminoethyl)-5-ethyl-5- phenyl-barbituric acid hydrochloride (L33 lbs.), is mixed with 37.33 lbs. of lactose and passed through a 30-mesh screen. A starch paste is prepared using 1.05 lbs. of cornstarch and 5.98 lbs. of distilled water. This prior mixture I EXAMPLE III A pharmaceutical suspension of 1-(2-diethylaminoethyl)--ethyI-S-phenylbarbituric acid is prepared by combining the following ingredients:
  • the foregoing liquid preparation provides a concentration of active ingredient at a level of 50 mgJcc. of which about 20 mg./cc. is in solution and the remainder in suspension.
  • Asep'toform M and P are trade names for esters of p-hydroxybenzoic acid which prevent fermentation and mold formation.
  • the foregoing preparation provides a concentration of the active ingredient, 1-(Z-diethylaminoethyl)-5-ethyl-5- phenylbarbituric acid, at a level of 2 mg./cc. or mg./teaspoon.
  • a pharmaceutical suppository of I-(Z-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid is prepared by melting 300 grams of spermacetti, U.S.P., and 695 grams of theobroma oil, U.S.P. The mixture is cooled to 50 C. and then 5 grams of 1-(2-diethylaminoethyl)-5-ethyl- S-phenyl-barbituric acid is added. The combined mixture 40 126, 132, 141 and 145.
  • the method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, at least about 10 mg. of a water-soluble salt of I-(Z-diethylaminoethyl -5-ethyl-5-phenylbarbituric acid.
  • the method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, at least about 10 mg. of a water-soluble salt of 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid andv a non-toxic pharmaceutical carrier.
  • the method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, about .150 mg. of a water-soluble salt of 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid.
  • the method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, at least about 10 mg. of 1-(Z-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid hydrochloride.
  • the method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, about 100 mg. of l-(Z-diethylaminoethyl)-5.-ethyl-5-phenylbarbituric acid hydrochloride.
  • the method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, at least about 100-150 mg.'ot I-(Z-diethylaminoethyl)-5-ethyl-5- phenylbarbituric acid hydrochloride and a non-toxic pharmaceutical carrier.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

United States Patent 2,995,489 METHOD OF OBTAINING PREANESTHETIC SE- DATION AND DRYING WITH 1-(2-DIETHYL- AMINOETHYL)-5-ETHYL 5 PHENYLBARBITU- RIC ACID John L. Schmidt, Highland Park, Ill., assignor to Abbott fitillioratorles, North Chicago, 111., a corporation bf 01s No Drawing. Filed July 12, 1957, Ser. No. 671,417 6 Claims. (Cl. 161-52) This invention relates to a new article of manufacture and to methods of compounding and using the same. More particularly, the invention relates to the compound, I-(Z-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid, in dosage unit form suitable for use as a preanesthetic composition. The compound 1-(2-diethylaminoethyl)-5- ethyl-S-phenylbarbituric acid and hydrochloride has the following structural formula:
It is a white, crystalline, hydrochloride salt which is soluble in water to a concentration of at least 2%. Solutions of this salt are stable at room temperature and begin to decompose only when subjected to prolonged boiling. The diethylaminoethyl side chain in the l-position provides the possibility for forming acid salts through the basic nitrogen atom in said side chain.
Among the desirable actions of a preanesthetic medicament are the counteracting of respiratory irregularities, cardiac irregularities and excessive flow of mucous and saliva. In general, such medication makes anesthesia more safe and comfortable for the patient and more etficient for the surgeon. Further usfulness resides in raising the patients threshold of reflex exitability to allow the use of inhalant anesthetics such as ethylene and nitrous oxide.
Most preanesthetic medications comprise a mixture of a narcotic such as morphine, meperidine, methadone or a barbiturate with an anti-sialogogue such as atrophine and scopolamine, that is, an agent which inhibits secretions of the respiratory tract and the salivary glands. The use of such mixtures, however, is accompanied by objectionable features such as diffuse pharmacological efiects on the entire organism and the other disadvantages associated with narcotic usage.
It is the object of this invention to provide in dosage unit forms a single compound possessing all the properties desirable in preanesthetic medications.
A further object is to prepare said dosage forms in solid and liquid carriers suitable for oral, suppository and injectable administration.
It has now been found that the compound, 1-(2-diethyaminoethyl)-5-ethyl-S-phenylbarbituric acid possesses properties which makes it highly desirable as a preanesthctic medicament. The compound causes inhibition of respiratory tract secretions and salivary gland secretion. It exhibits a further action in counteracting cardiac arrhythmic, that is, it maintains normal cardiac rhythm. This latter condition is often disrupted in the subsequent state of general anesthesia. Furthermore, it is expected that it will reduce reflex excitability and apprehension.
The effective clinical dose for adults ranges from about 10 mg. per day upwardly when injected directly into the circulatory body fluids of the patient. In children, the dosage ranges are correspondingly lower according to age and weight of the child. This drug may be adnun- Patented Aug. 8, 1961 istered by hypodermic syringe in the form of a sterile water solution of said compound prepared to the desired concentration. The compound can be made available n said fresh solution form or in powder form present in capsules or vials and other carriers which allow easy conversion to the solution form. The drug may be also administered orally in the form of tablets, capsules, powder or in a flavored, liquid form. A suppository form for rectal administration can also be prepared by combining the drug with appropriate waxes.
A preferred form of oral administration is 10 mg. scored tablets which will provide the minimum dose for children and will provide, in multiples, amounts up to the maximum dose. In one of the preferred forms, the
active ingredient, l-(2-diethylaminoethyl)-5-ethyl-5-phenthe active material with or without its adjuvant materials may be placed in a soft or hard gelatin capsule and administered in capsule form.
In another embodiment of the invention, a solution dose form is made. The solubility of the active compound, while limited, is still sufiicient to prepare a dosage level suitable for therapeutic administration. A solution dosage form can contain from about 2 ing/cc. to 5 mg./cc. of active ingredient (10 to 25/mg. per teaspoon). A liquid pharmaceutical dosage form of greater concentration may also be prepared by compounding the active material with suspending agents such as acacia or carboxymethylcellulose along with the usual flavoring materials. Such a liquid preparation is particularly suitable for children and infirm persons who have difficulty swallowing a tablet or capsule.
Sterile, isotonic, liquid forms are prepared for injection into the body by placing the desired amount of active ingredient into sterile water, adjusting the osmotic tension to coincide with the osmotic tension of body fluids, sealing said solution in an ampoule and sterilizing said ampoule.
The following examples illustrate preferred embodiments of the dosage forms, but it should be understood that they are not meant to restrict the dosage forms to the ingredients and proportions named thereinf EXAMPLE I A solution of I-(Z-diethylaminoethyl)-5-ethyl-5-phenyl-barbituric acid hydrochloride is prepared byadding 20 mg. of said l-(Z-diethylaminoethyl)-5-ethyl-S-phenylbarbituric acid to each cc. of water. The solution is made isotonic to physiological fluids by adding sodium chloride and thereafter the solution is filtered. From this solution, a 10 cc. aliquot is placed in an ampoule and the ampoule is then sealed. The ampoules are sterilized in an autoclave at 121 C. at 10 lbs. pressure for 20 minutes. Immediately thereafter the ampoules are removed and cooled in running water. The prepared ampoulcs contain a 2% solution of l-(2-diethyluminoethyl)-5-ethyl-5- phenylbarbituric acid which is suitable for introduction into the body by injection.
EXAMPLE II The compound, 1 (Z-diethylaminoethyl)-5-ethyl-5- phenyl-barbituric acid hydrochloride (L33 lbs.), is mixed with 37.33 lbs. of lactose and passed through a 30-mesh screen. A starch paste is prepared using 1.05 lbs. of cornstarch and 5.98 lbs. of distilled water. This prior mixture I EXAMPLE III A pharmaceutical suspension of 1-(2-diethylaminoethyl)--ethyI-S-phenylbarbituric acid is prepared by combining the following ingredients:
l-(2-diethylaminoethyl )-5-phenylbarbituric acid hydrochloride grams 50 Sodium carboxymethylcellulose, medium viscosity grams 8.0 Sucrose do. 100 Aseptoform M do 1.5 Aseptoform P do 0.15 F.D.&C. Green #1 do 0.05 Imitation cherry cc 0.75
Water, deionized, q.s.;'1000.0 Co.
The foregoing liquid preparation provides a concentration of active ingredient at a level of 50 mgJcc. of which about 20 mg./cc. is in solution and the remainder in suspension.
Asep'toform M and P are trade names for esters of p-hydroxybenzoic acid which prevent fermentation and mold formation.
EXAMPLE IV 1-(Z-dielhylaminoethyl)-5-ethyI-S-phenylbarbituric in solution dose form acid A pharmaceutical solution of 1-(2-diethylaminoethyl)- 5-ethyl-S-phenylbarbituric acid is prepared by combining the following ingredients:
l-(Z-diethylaminoethyl)-5-ethyl-S-phenylbarbituric acid hydrochloride "grams" 2.0 Sucrose "do-.." 200.0 Glycerin -cc 150.0 Aseptoform M grams 1.5 Aseptoform P do 0.15 F.D.&C. Orange #1 do.. 0.05 Imitation orange aroma ..cc.... 0.02 Oil orange cc 0.5
Water, Ilco, q.s., 1000.0 cc.
The foregoing preparation provides a concentration of the active ingredient, 1-(Z-diethylaminoethyl)-5-ethyl-5- phenylbarbituric acid, at a level of 2 mg./cc. or mg./teaspoon.
EXAMPLE V A pharmaceutical suppository of I-(Z-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid is prepared by melting 300 grams of spermacetti, U.S.P., and 695 grams of theobroma oil, U.S.P. The mixture is cooled to 50 C. and then 5 grams of 1-(2-diethylaminoethyl)-5-ethyl- S-phenyl-barbituric acid is added. The combined mixture 40 126, 132, 141 and 145.
is stirred to a state of uniformity and then delivered to individual molds and chilled. The molds yield suppositories weighing 2 grams, which melt at 50 C. Each suppository contains 10 mg. of active material.
Others may practice the invention in any of the numerous ways which will be suggested by this disclosure to one skilled in the art. All such practice of the invention is considered to be a part hereof provided it falls within the scope of the appended claims.
' lclaim:
1. The method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, at least about 10 mg. of a water-soluble salt of I-(Z-diethylaminoethyl -5-ethyl-5-phenylbarbituric acid.
2. The method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, at least about 10 mg. of a water-soluble salt of 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid andv a non-toxic pharmaceutical carrier.
3. The method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, about .150 mg. of a water-soluble salt of 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid.
4. The method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, at least about 10 mg. of 1-(Z-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid hydrochloride.
5. The method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, about 100 mg. of l-(Z-diethylaminoethyl)-5.-ethyl-5-phenylbarbituric acid hydrochloride.
6. The method of obtaining preanesthetic sedation and drying conditions which comprises administering to a human, prior to inducing general anesthesia, at least about 100-150 mg.'ot I-(Z-diethylaminoethyl)-5-ethyl-5- phenylbarbituric acid hydrochloride and a non-toxic pharmaceutical carrier.
References Cited in the file. of this patent UNITED STATES PATENTS Olinger Apr. 15, 1958 OTHER REFERENCES Dripps: Introduction to Anesthesia, W. B. Saunders Co., Phila., Pa., 1957, pp. 9-16.
Trochimowski: Arch. Chemiji I Framac l (Poland),
vol. 2, 1934, pp. 1-8.

Claims (1)

  1. 2. THE METHOD OF OBTAINING PREANESTHETIC SEDATION AND DRYING CONDITIONS WHICH COMPRISES ADMINISTERING TO A HUMAN, PRIOR TO INDUCING GENERAL ANESTHESIA, AT LEAST ABOUT 10 MG. OF A WATER-SOLUBLE SALT OF 1-(2-DIETHYLAMINOETHYL)-5-ETHYL-5-PHENYLBARBITURIC ACID AND A NON-TOXIC PHARMACEUTICAL CARRIER.
US671417A 1957-07-12 1957-07-12 Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid Expired - Lifetime US2995489A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US671417A US2995489A (en) 1957-07-12 1957-07-12 Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US671417A US2995489A (en) 1957-07-12 1957-07-12 Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid

Publications (1)

Publication Number Publication Date
US2995489A true US2995489A (en) 1961-08-08

Family

ID=24694433

Family Applications (1)

Application Number Title Priority Date Filing Date
US671417A Expired - Lifetime US2995489A (en) 1957-07-12 1957-07-12 Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid

Country Status (1)

Country Link
US (1) US2995489A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3150137A (en) * 1964-09-22 Carbamate derivative of s-hydroxy-
US3335184A (en) * 1963-07-26 1967-08-08 Exploitations Chimi & Pharm Ortho-diisopropylaminoethoxybutyrophenone and hydrochloride thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830930A (en) * 1955-08-08 1958-04-15 Jr Allen M Olinger Parenteral dental local anesthetic solutions containing an alkantheline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830930A (en) * 1955-08-08 1958-04-15 Jr Allen M Olinger Parenteral dental local anesthetic solutions containing an alkantheline

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3150137A (en) * 1964-09-22 Carbamate derivative of s-hydroxy-
US3335184A (en) * 1963-07-26 1967-08-08 Exploitations Chimi & Pharm Ortho-diisopropylaminoethoxybutyrophenone and hydrochloride thereof

Similar Documents

Publication Publication Date Title
SADOVE et al. Analgesic effects of ketamine administered in subdissociative doses
US3849549A (en) Indomethacin suppositories
JPS59112948A (en) Cholesterol level lowering agent
Mandel et al. Intravenous use of pituitary adrenocorticotropic hormone (ACTH): a report on its administration in twenty-five patients
US2995489A (en) Method of obtaining preanesthetic sedation and drying with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid
US2995491A (en) Method of treating cardiac arrhythmia with 1-(2-diethylaminoethyl)-5-ethyl-5-phenylbarbituric acid
HODES et al. Fulminating meningococcemia treated with cortisone; use of blood eosinophil count as a guide to prognosis and treatment
US3644643A (en) Method of reducing intraocular pressure using glycine
Hilker Agranulocytosis from Tripelennamine (Pyribenzamine®) Hydrochloride
US2916417A (en) Article of manufacture
US3077435A (en) Therapeutic composition comprising 4-(2-dimethylaminoethoxy)-4-(3, 4, 5-trimethoxybenzoyl)-benzylamine and betapyridylcarbinol
HURXTHAL PITUITARY GIGANTISM IN A CHILD FIVE YEARS OF AGE: EFFECT OF X-RADIA-TION, ESTROGEN THERAPY AND SELF-IMPOSED STARVATION DIET DURING AN ELEVENYEAR PERIOD
US2991225A (en) Omicron-methylbenzhydryl-beta-dimethylaminoethyl ether process and composition for symptomatic relief of the syndrome of parkinsonism and of spastic skeletal muscle disorders
Diddle et al. Comparative Clinical Effects of Orally Administered Alpha-Estradiol and Diethylstilbestrol on Postpartum Engorgement of the Breast
US3660574A (en) Method of controlling fertility employing quingestanol acetate
US2766174A (en) Self-sterilizing antihistaminic solution of 3-(p-chlorophenyl)-3-(2-pyridyl)-n, n-dimethyl propylamine
JPS6116A (en) Improvements related to organic compounds
Comroe Atropine poisoning: recovery after 7½ grains of atropine sulphate by mouth
US2061557A (en) Anesthetic combinations containing, besides a local anesthetic agent, a vasoconstricting agent
Hine et al. Fatality after use of alphaprodine in analgesia for dental surgery: report of case
Weisman et al. The treatment of acute staphylococcic infections with sulfamethylthiazol
Poe et al. Seconal as a Basal Anesthetic for Children.
Edson Treatment of organophosphorus poisoning
IL34670A (en) Pharmaceutical compositions containing 2-(2,6-dichlorophenyl-amino)-1,3-diazacyclopentene-(2)and/or acid addition salts thereof
THOMPSON et al. Oral and Duodenal Administration of Single Large Doses of Pure Thyroxine: Comparison of Calorigenic Effects with Those of Monosodium Thyroxine and Thyroxine in Alkaline Solution